Sunshine Biopharma (SBFM) Current Assets (2010 - 2026)

Sunshine Biopharma's Current Assets history runs 16 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• Quarterly Current Assets rose 1.23% year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.8 million (up 1.23% YoY) and the FY2025 annual result came in at $26.9 million, up 3.42% from the prior year.
• Current Assets was $24.8 million for Q1 2026 at Sunshine Biopharma, down from $26.9 million in the prior quarter.
• Across five years, Current Assets topped out at $42.0 million in Q2 2022 and bottomed at $13.4 million in Q1 2022.
• A 5-year average of $27.3 million and a median of $26.0 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets jumped 2228.1% — and 2023, when it slumped 37.84%.
• Sunshine Biopharma's Current Assets stood at $27.3 million in 2022, then dropped by 8.87% to $24.9 million in 2023, then gained by 4.32% to $26.0 million in 2024, then increased by 3.42% to $26.9 million in 2025, then slipped by 7.71% to $24.8 million in 2026.
• Business Quant data shows SBFM's Current Assets at $24.8 million in Q1 2026, $26.9 million in Q4 2025, and $28.0 million in Q3 2025.